Phase
Condition
Macular Edema
Treatment
vitrectomy + ILM peeling +/- planned foveal detachment via subretinal injection of ringer's solution.
Clinical Study ID
Ages 40-80 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Age: above 40 years old.
Patients with type two diabetes mellitus of more than 5 years duration.
Patients with Best corrected visual acuity better than 3/60.
Central macular thickness (CMT) of more than 250 μm despite undergoing sixmonthly injection of anti-VEGF therapy or corticosteroid or less than 10%reduction in CMT at the last follow up visit.
No evidence of vitreomacular traction.
Lens status: Pseudophakia or clear crystalline lens.
Exclusion
Exclusion Criteria:
Other causes of macular edema (intraocular inflammation, retinal vein occlusion, Irvin-gass syndrome, pharmacological).
Ischemic maculopathy by FFA.
Presence of bad prognostic signs in OCT such as disorganization of inner retinallayers (DRIL) and extensive disruption of IS-OS junction subfoveally.
Presence of apparent retinal pigment epithelium (RPE) atrophy at or near the macula.
Presence of proliferative diabetic fibrovascular membranes threatening or at themacula.
Presence of diabetic optic atrophy or neuropathy.
Presence of neovascular glaucoma.
Cataractous lens either preoperatively or as intra or postoperative complication.
Vitrectomized Eyes.
A prior intraocular surgery within the past six-months.
Lost follow up
Study Design
Study Description
Connect with a study center
Ain Shams university
Cairo,
EgyptActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.